COMPASS Pathways (NASDAQ:CMPS) Announces Earnings Results

COMPASS Pathways (NASDAQ:CMPS) issued its earnings results on Thursday. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01), Zacks reports.

COMPASS Pathways Stock Performance

Shares of COMPASS Pathways stock traded up $0.03 during trading on Friday, reaching $3.95. The company’s stock had a trading volume of 475,183 shares, compared to its average volume of 1,251,092. COMPASS Pathways has a 52 week low of $3.16 and a 52 week high of $12.57. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $4.06 and its 200-day moving average price is $5.28. The firm has a market cap of $270.47 million, a PE ratio of -1.79 and a beta of 2.28.

Analyst Upgrades and Downgrades

CMPS has been the subject of a number of research analyst reports. Stifel Nicolaus began coverage on COMPASS Pathways in a research note on Thursday. They issued a “buy” rating and a $11.00 target price for the company. Canaccord Genuity Group decreased their price objective on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright dropped their target price on shares of COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Maxim Group reduced their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $21.83.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.